Global Diabetes Drug Market was valued at USD 47.2 Billion in the year 2017. Global Diabetes Drug Market is further estimated to grow at a CAGR of 7.09% from 2018 to reach USD 70.9 Billion by the year 2023. North America region holds the highest market share in 2017 and Asia-Pacific is considered as the fastest growing market in the forecasted period. At country level, developed markets U.S holds a substantial market share in 2017 and it is projected to grow at a gradual pace in the coming years.

Abbott Laboratories (U.S.), Novartis AG (Switzerland), Novo Nordisk (Denmark), Bayer Healthcare AG (Germany) , Johnson & Johnson (U.S) and Sanofi (France) are some of the key players in the Diabetes Drug Market with Novo Nordisk (Denmark) holding the significant market share because of its better global presence both at production and at an operational level. Rising research and development expenses to address the changing demand of end users, similarly growth strategies such as acquisition, merger and expansion of the distribution network were few techniques adopted by most of the top players in the last 5 years.

Request a Sample Copy @ https://goo.gl/3dqhuF

The major Key Market Players
Abbott Laboratories
AstraZeneca PLC
Bayer Healthcare AG
Dexcom Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Sanofi
Merck & Co.
Novartis AG
Novo Nordisk

On the basis of Application, the market is primarily split into
Type 1 Diabetes
Type 2 Diabetes

Browse Complete Report @ https://goo.gl/XncYZ4
Table Of Content:
1. Introduction
1.1 Market Vision
1.1.1 Market Definition
1.1.2 Market Scope
1.2 Limitations
1.3 Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.1.1. Key Data from Secondary Research
2.1.2. Primary Research
2.1.2.1. Key Data from Primary Research
2.1.2.2. Breakdowns of Primary Interviews
2.2. Market Size Estimation
2.2.1. Bottoms-Up Approach
2.2.2. Top-Down Approach
2.2.3. Annual Revenue Process
2.3. Data Triangulation
2.4. Research Assumptions
2.4.1. Assumption
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Challenges
4.6. Regulations
4.7. Supply Chain/Value Chain Analysis
4.8. Patent & Standards
5. Industry Trends
5.1. Introduction
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Buyers
5.2.4. Bargaining Power of Suppliers
5.2.5. Intensity of Competitive Rivalry
6. Diabetes Drug Market, By Products & Services
6.1. Insulin Derivatives
6.1.1 Rapid-acting insulin
6.1.2 Intermediate-acting insulin
6.1.3 Long-acting insulin
6.2. Oral Diabetic Medication Drugs
6.2.1 Sulfonylurea
6.2.2 Metformin
6.2.3 Alpha-Glucosidase inhibitor
6.2.4 Thiazolidinediones
6.2.5 Biguanide
6.2.6 Meglitinides
6.2.7 GPP4-Inhibitors
6.3 GLP-1
7. Diabetes Drug Market, By Application
7.1. Type 1 Diabetes
7.2. Type 2 Diabetes
8. Geographical Analysis
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. U.K.
8.3.2. Germany
8.3.3. Italy
8.3.4. France
8.3.5. RoE
8.4. Asia Pacific
8.4.1. South Korea
8.4.2. China
8.4.3. Japan
8.4.4. South Korea
8.4.5. RoAPAC
8.5. RoW
8.5.1. Latin America
8.5.2. Middle East and Africa
9. Company Profiles
(Business Overview, Financial Overview, Product write Up, Recent Developments)
9.1. Abbott Laboratories
9.2 AstraZeneca PLC
9.3 Bayer Healthcare AG
9.4 Dexcom Inc.
9.5 GlaxoSmithKline PLC
9.6 Johnson & Johnson
9.7 Sanofi
9.8 Merck & Co.
9.9 Novartis AG
9.10 Novo Nordisk

(Another brief information of 10 companies will be provided in report.)

10. Competitive Analysis
10.1. Introduction
10.2. Market Positioning of Key Players
10.3 Competitive Strategies Adopted by Leading Players
10.3.1. Investments & Expansions
10.3.2. New Product Launches
10.3.3. Mergers & Acquisitions
10.3.4. Agreements, Joint Ventures, and Partnerships
11. Appendix
11.1. Questionnaire
11.2. Available Customizations
11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

Purchase Complete report @ https://goo.gl/2kSxxK

About Us:
Genesis Market Insights (GMI), is a subsidiary of Genesis Management & Market Research Pvt.Ltd. (GMMR) having a strong experience both in primary and secondary market research serving small to large scale enterprises across globe. Established in 1993, GMMR has become a recommended brand for Market Research for various international and MNC Corporations with its strong data foundation. With its exhaustive research capabilities, strong analytics services and in house data validation tools, GMMR has delivered actionable, reliable and all-inclusive Market Research Reports.

Contact us:
Email- [email protected]